Express Scripts (ESRX) Deal is Huge Win for VIVUS (VVUS); Qsymia Reimbursement Will Improve

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. SPY
3. GLOB
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Express Scripts (ESRX) Deal is Huge Win for VIVUS (VVUS); Qsymia Reimbursement Will Improve

JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting

December 21, 2012 11:56 AM EST

Orexigen Therapeutics (Nasdaq: OREX) shares are up on the session following a little pressure earlier in the week on its Contrave NDA resubmission.

JPMorgan is out with comments following Orexigen's analyst day this week. The firm remains confident on approvability of Contrave and that any good news from Arena Pharmaceuticals (Nasdaq: ARNA) and VIVUS, Inc. (Nasdaq:... More

Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)

December 20, 2012 6:34 AM EST

VIVUS, Inc. (NASDAQ: VVUS) peers Arena Pharmaceutials (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) are ticking higher following reports that major Pharmacy Benefit Manager (PBM) Express Scripts (Nasdaq:... More

VIVUS (VVUS) Says Qsymia Now Covered by Express Scripts' (ESRX)

December 20, 2012 6:31 AM EST

VIVUS, Inc. (NASDAQ: VVUS) today announced that Express Scripts (Nasdaq: ESRX), among the country's largest Pharmacy Benefit Managers (PBMs), has added Qsymia to its national pharmacy formularies, allowing for coverage where available by benefit design of the first... More